Journal Browser

► Journal Browser

Special Issue "Bioactive Compounds from Marine Streptomyces 2nd Edition"

Share This Special Issue

Special Issue Editor

E-Mail Website
Guest Editor

South China Seas Institute of Oceanography Chinese Academy of Sciences, Guangzhou, China
Interests: marine natural products; biosynthesis; marine microorganisms; anti-infective; antitumor
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine Streptomyces has emerged as an important resource for bioactive natural products due to their unique physiological and metabolic functions. The natural products derived from marine Streptomyces exhibit a variety of bioactive properties, especially in the antitumor and antibacterial areas, holding great promise for applications in the agricultural and pharmaceutical fields. Genetic manipulation technologies have also been applied in the search for new bioactive natural products from marine Streptomyces.

Given the success of the previous Special Issue “Bioactive Compounds from Marine Streptomyces, https://www.mdpi.com/journal/marinedrugs/special_issues/marine_Streptomyces", and the relevant interest in this topic, we are pleased to announce the second version of this Special Issue.

This Special Issue invites the submission of research papers or reviews focused on bioactive compounds from marine Streptomyces isolated by traditional methods or produced by the application of synthetic biology techniques, chemical modification from marine natural product lead compounds, and pharmacological research highlighting progress in the following topics: bioactivity screening; novel natural product discovery; structural characterization; genome mining; elucidation of biosynthetic pathways; genomics- and metabolomics-driven studies; chemical synthesis; and potential applications.

Prof. Dr. Jianhua Ju
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Saquayamycin B₁ Suppresses Proliferation, Invasion, and Migration by Inhibiting PI3K/AKT Signaling Pathway in Human Colorectal Cancer Cells

and

Mar. Drugs 2022, 20(9), 570; https://doi.org/10.3390/md20090570 - 07 Sep 2022

Cited by 3 | Viewed by 1327

Abstract

Moromycin B (Mor B), saquayamycin B₁ (Saq B₁), saquayamycin B (Saq B), and landomycin N (Lan N), four angucyclines produced by the marine-derived actinomycete Streptomyces sp., are a class of polyketone compounds containing benzanthracene. Here, the structure–activity relationship of these four compounds was analyzed in human colorectal cancer (CRC) cells. Saq B₁, which showed the strongest cytotoxicity with an IC₅₀ of 0.18–0.84 µM for CRC cells in MTT assays, was employed to test underlying mechanisms of action in SW480 and SW620 cells (two invasive CRC cell lines). Our results showed that Saq B₁ inhibited CRC cell proliferation in a dose- and time-dependent manner. Notably, lower cytotoxicity was measured in normal human hepatocyte cells (QSG-7701). Furthermore, we observed proapoptosis, antimigration, and anti-invasion activities of Saq B₁ in CRC cells. At the same time, the protein and mRNA expression of important markers related to the epithelial–mesenchymal transition (EMT) and apoptosis changed, including N-cadherin, E-cadherin, and Bcl-2, in Saq B₁-treated CRC cells. Surprisingly, the PI3K/AKT signaling pathway was shown to be involved in Saq B₁-induced apoptosis, and in inhibiting invasion and migration. Computer docking models also suggested that Saq B₁ might bind to PI3Kα. Collectively, these results indicate that Saq B₁ effectively inhibited growth and decreased the motor ability of CRC cells by regulating the PI3K/AKT signaling pathway, which provides more possibilities for the development of drugs in the treatment of CRC. Full article

(This article belongs to the Special Issue Bioactive Compounds from Marine Streptomyces 2nd Edition)

► Show Figures

Figure 1

Open AccessArticle

Halo- and Thiocarbazomycins from Coral- and Coral Reef Sands-Derived Actinomycetes

and

Mar. Drugs 2022, 20(8), 537; https://doi.org/10.3390/md20080537 - 21 Aug 2022

Cited by 1 | Viewed by 1468

Abstract

Four actinomycete strains isolated from the coral Acropora austera and coral sand samples from the South China Sea, were found to produce a series of halogenated compounds baring similar ultraviolet absorption based on the analysis of HPLC and LC-MS. The production titers of halogenated compounds from Streptomyces diacarni SCSIO 64983 exceeded those of other similar strains leading us to focus on SCSIO 64983. Four new thiocarbazomycins A–B (1–2), chlocarbazomycin E (3), and brocarbazomycin A (4), together with three known chlocarbazomycins A–C (5–7) containing a carbazole core were identified, and their structures were determined using a combination of spectroscopic analysis including HRESIMS, 1D and 2D NMR. Structurally speaking, compounds 1 and 2 have the rare sulfur-containing carbazole nuclei, and 3 and 4 contain Cl and Br atoms, respectively. Although these compounds have not yet been found to have obvious biological activity, their discovery highlights the role of molecular libraries in subsequent drug discovery campaigns. Full article

(This article belongs to the Special Issue Bioactive Compounds from Marine Streptomyces 2nd Edition)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Bioactive Compounds from Marine Streptomyces 2nd Edition"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Related Special Issue

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI